Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5885, GS-9451, Tegobuvir, and Ribavirin in Treatment-Experienced Chronic HCV
NCT01435226Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ledipasvir, vedroprevir, tegobuvir in hepatitis C virus infection, sponsored by Gilead Sciences. Started Sep 2011; status: completed.
02
Drugs
ledipasvirvedroprevirtegobuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01435226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01435226.